search
Back to results

Early Phase II Trials for Cocaine Medication Development - 1

Primary Purpose

Cocaine-Related Disorders, Substance-Related Disorders

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Risperidone
Placebo
Relapse prevention counseling
Sponsored by
New York State Psychiatric Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cocaine-Related Disorders focused on measuring Cocaine, METHADONE PATIENTS, RISPERIDONE

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion: good standing at methadone maintenance program DSM-IV criteria for cocaine dependence or abuse used cocaine at least 4 times in last month able to give informed consent Exclusion criteria currently meets DSM-IV criteria for Major depression or dysthymia meets DSM-IV criteria for attention deficit hyperactivity disorder, bipolar disorder, schizophrenia or any psychotic disorder history of seizures history of allergic reaction to risperidone chronic organic mental disorder significant current suicidal risk pregnancy, lactation or failure to use adequate birth control (for females) unstable physical disorders that may make participation hazardous coronary vascular disease cardiac conduction system disease as indicated by QRS duration >/= 0.11 current use of other prescribed psychotropic medications history of failure to respond to a previous adequate trial of risperidone history of neuroleptic malignant syndrome, tardive dyskinesia, or severe extrapyramidal reactions to neuroleptic medications current DSM-IV criteria for another substance dependence other than nicotine.

Sites / Locations

  • NYS Psychiatric Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

PLacebo

Risperidone

Arm Description

Placebo plus relapse prevention counseling

Risperidone (4mg/day) plus relapse prevention counseling

Outcomes

Primary Outcome Measures

Side effects
Using the Modified Systemic Assessment for Treatment Emergent Effects the psychiatrist assessed side effects
Craving
subjective cravings were recorded on the Cocaine craving scale
Drug use
urine drug testing and self reported use on the Substance Use Weekly Inventory
Retention
duration of individuals in the study.

Secondary Outcome Measures

Full Information

First Posted
September 20, 1999
Last Updated
June 22, 2017
Sponsor
New York State Psychiatric Institute
Collaborators
National Institute on Drug Abuse (NIDA), Research Foundation for Mental Hygiene, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00000317
Brief Title
Early Phase II Trials for Cocaine Medication Development - 1
Official Title
Early Phase II Trials for Cocaine Medication Development
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
August 1996 (Actual)
Primary Completion Date
July 1999 (Actual)
Study Completion Date
July 1999 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
New York State Psychiatric Institute
Collaborators
National Institute on Drug Abuse (NIDA), Research Foundation for Mental Hygiene, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This
Detailed Description
This was an 18-week prospective, randomized, placebo-controlled crossover design with placebo lead-in phase and terminal placebo phase. After two weeks of single-blind placebo, patients were randomly assigned to one of two schedules of medication: 2 Week Baseline Weeks 1-6 Weeks 7-12 Weeks 13-18 Group 1 placebo risperidone placebo placebo Group 2 placebo placebo risperidone placebo The first 6-week phase provided an initial double-blind medication-placebo comparison. In the second six-week phase (weeks 7-12), patients crossed over to the opposite treatment. During weeks 13-18, Group 1 patients remained on placebo while Group 2 patients were tapered from risperidone to placebo. For six weeks after the end of the trial, patients were offered routine clinical treatment with counseling and psychiatrist visits as needed. Medication dosage was titrated upwards on a fixed-flexible schedule to a maximum dose of 4 mg per day. Medication began at ½ mg risperidone for 3 days, then 1 mg for four days, 2 mg per day during week 2, 3 mg per day during week 3, and 4 mg per day during weeks 4-6. The titration schedule for risperidone in weeks 7-12 was the same as for weeks 1-6. In addition to treatment as usual, patients received a modified manual-guided relapse prevention counseling program in weekly meetings lasting approximately 20 minutes; these sessions provided cognitive and behavioral skills that were found to be helpful to patients in reducing cocaine use.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cocaine-Related Disorders, Substance-Related Disorders
Keywords
Cocaine, METHADONE PATIENTS, RISPERIDONE

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PLacebo
Arm Type
Placebo Comparator
Arm Description
Placebo plus relapse prevention counseling
Arm Title
Risperidone
Arm Type
Experimental
Arm Description
Risperidone (4mg/day) plus relapse prevention counseling
Intervention Type
Drug
Intervention Name(s)
Risperidone
Other Intervention Name(s)
Risperidal
Intervention Description
Risperidone (4mg/day)
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Intervention Type
Behavioral
Intervention Name(s)
Relapse prevention counseling
Other Intervention Name(s)
RPT-CBT
Intervention Description
Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.
Primary Outcome Measure Information:
Title
Side effects
Description
Using the Modified Systemic Assessment for Treatment Emergent Effects the psychiatrist assessed side effects
Time Frame
1x/week for 18 weeks
Title
Craving
Description
subjective cravings were recorded on the Cocaine craving scale
Time Frame
3x/week during 18 weeks of trial
Title
Drug use
Description
urine drug testing and self reported use on the Substance Use Weekly Inventory
Time Frame
3x/week during 18 weeks of trial
Title
Retention
Description
duration of individuals in the study.
Time Frame
18 weeks or length of study participation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion: good standing at methadone maintenance program DSM-IV criteria for cocaine dependence or abuse used cocaine at least 4 times in last month able to give informed consent Exclusion criteria currently meets DSM-IV criteria for Major depression or dysthymia meets DSM-IV criteria for attention deficit hyperactivity disorder, bipolar disorder, schizophrenia or any psychotic disorder history of seizures history of allergic reaction to risperidone chronic organic mental disorder significant current suicidal risk pregnancy, lactation or failure to use adequate birth control (for females) unstable physical disorders that may make participation hazardous coronary vascular disease cardiac conduction system disease as indicated by QRS duration >/= 0.11 current use of other prescribed psychotropic medications history of failure to respond to a previous adequate trial of risperidone history of neuroleptic malignant syndrome, tardive dyskinesia, or severe extrapyramidal reactions to neuroleptic medications current DSM-IV criteria for another substance dependence other than nicotine.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Edward Nunes, M.D.
Organizational Affiliation
NYS Psychiatric Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
NYS Psychiatric Institute
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Early Phase II Trials for Cocaine Medication Development - 1

We'll reach out to this number within 24 hrs